This summer, I had the opportunity to attend the 46 th  Annual Conference of the International Society for Clinical Biostatistics (ISCB) in Basel. It was an incredible week of learning and networking with biostatisticians from around the world. As my first academic conference, the experience was both exciting and a little overwhelming – with multiple parallel sessions running at once, there was so much to explore and absorb.  The two keynote presentations particularly stood o

When patients stop taking their assigned treatment in a clinical trial - whether due to side effects, lack of effectiveness, or personal...

The Imperial Clinical Trials Unit (ICTU) team had the pleasure of attending the International Clinical Trials Methodology Conference...

The US Food and Drug Administration’s (FDA) guidance document on decentralised clinical trials (DCTs) published in September 2024 is a...

Within the trial’s community, we are regularly talking about more efficient designs such as adaptive designs and decentralising elements...